ClinicalTrials.gov
public full text
Public Domain
Open Label Study of TRx0014 in Alzheimer's Disease
This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical trial designated TRx-014-001 at termination of that study. Treatment for each individual patient will continue for as long as the treating physician feels there is benefit to the patient. This current protocol covers each patient for 12 months in the first instance.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment#855544
- Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's#1362811
- Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease#1296182
- Comparative Bioavailability in Healthy Elderly Volunteers#801180
- Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease#1045505
Record · ID 1340465
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive